View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsGenocea Biosciences 과거 순이익 실적과거 기준 점검 0/6Genocea Biosciences은 연평균 13.2%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 33.8%의 비율로 증가했습니다. 매출은 연평균 40.6%의 비율로 증가했습니다.핵심 정보13.19%순이익 성장률32.93%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률40.62%자기자본이익률-300.29%순이익률-1,946.15%최근 순이익 업데이트31 Mar 2022최근 과거 실적 업데이트Reported Earnings • Mar 13Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: US$0.48 loss per share (up from US$0.98 loss in FY 2020). Net loss: US$33.2m (loss narrowed 24% from FY 2020). Products in clinical trials Phase I: 2 Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 77%. Over the next year, revenue is expected to shrink by 100% compared to a 60% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.Reported Earnings • Oct 30Third quarter 2021 earnings released: US$0.052 loss per share (vs US$0.082 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$3.62m (loss narrowed 21% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updatesPrice Target Changed • Apr 27Price target decreased to US$5.74Down from US$6.74, the current price target is an average from 5 analysts. New target price is 1,300% above last closing price of US$0.41. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$0.78 next year compared to a net loss per share of US$0.48 last year.Price Target Changed • Apr 11Price target decreased to US$5.74Down from US$6.70, the current price target is an average from 5 analysts. New target price is 857% above last closing price of US$0.60. Stock is down 77% over the past year. The company is forecast to post a net loss per share of US$0.75 next year compared to a net loss per share of US$0.48 last year.Reported Earnings • Mar 13Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: US$0.48 loss per share (up from US$0.98 loss in FY 2020). Net loss: US$33.2m (loss narrowed 24% from FY 2020). Products in clinical trials Phase I: 2 Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 77%. Over the next year, revenue is expected to shrink by 100% compared to a 60% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.Price Target Changed • Mar 11Price target increased to US$7.67Up from US$6.68, the current price target is an average from 3 analysts. New target price is 555% above last closing price of US$1.17. Stock is down 60% over the past year. The company is forecast to post a net loss per share of US$0.46 next year compared to a net loss per share of US$0.98 last year.Board Change • Dec 06Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Jennifer Herron was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 30Third quarter 2021 earnings released: US$0.052 loss per share (vs US$0.082 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$3.62m (loss narrowed 21% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.분석 기사 • Jun 17Here's Why Shareholders May Want To Be Cautious With Increasing Genocea Biosciences, Inc.'s (NASDAQ:GNCA) CEO Pay PacketThe underwhelming share price performance of Genocea Biosciences, Inc. ( NASDAQ:GNCA ) in the past three years would...Executive Departure • Apr 16Independent Director has left the companyOn the 12th of April, Ronald H. Cooper's tenure as Independent Director ended after 4.8 years in the role. We don't have any record of a personal shareholding under Ronald H.'s name. A total of 2 executives have left over the last 12 months.Recent Insider Transactions Derivative • Feb 21President exercised options to buy US$132k worth of stock.On the 17th of February, William Clark exercised options to buy 36k shares at a strike price of around US$2.24, costing a total of US$82k. This transaction amounted to 165% of their direct individual holding at the time of the trade. Since March 2020, William's direct individual holding has increased from 17.42k shares to 19.75k. Company insiders have collectively bought US$92k more than they sold, via options and on-market transactions, in the last 12 months.분석 기사 • Feb 18What Type Of Returns Would Genocea Biosciences'(NASDAQ:GNCA) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?Genocea Biosciences, Inc. ( NASDAQ:GNCA ) shareholders will doubtless be very grateful to see the share price up 77% in...Analyst Estimate Surprise Post Earnings • Feb 12Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 2.9%. Earnings per share (EPS) exceeded analyst estimates by 2.9%. Over the next year, revenue is expected to shrink by 67% compared to a 819% growth forecast for the Biotechs industry in the US.Is New 90 Day High Low • Feb 04New 90-day high: US$3.30The company is up 37% from its price of US$2.41 on 05 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 24% over the same period.분석 기사 • Jan 14How Much Of Genocea Biosciences, Inc. (NASDAQ:GNCA) Do Institutions Own?Every investor in Genocea Biosciences, Inc. ( NASDAQ:GNCA ) should be aware of the most powerful shareholder groups...Is New 90 Day High Low • Dec 24New 90-day high: US$2.67The company is up 26% from its price of US$2.12 on 24 September 2020. The American market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Oct 31New 90-day low: US$2.08The company is down 27% from its price of US$2.85 on 31 July 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$11.76 per share.Analyst Estimate Surprise Post Earnings • Oct 31Third-quarter earnings released: Earnings beat expectationsEarnings per share (EPS) surpassed analyst estimates by 69% at -US$0.08. Revenue is expected to shrink by 76% over the next year, compared to a 293% growth forecast for the Biotechs industry in the US.Major Estimate Revision • Oct 30Analysts increase EPS estimates to -US$1.07The 2020 consensus revenue estimate increased from US$922.4k to US$937.3k. Analysts raised their EPS forecasts from -US$1.21 to -US$1.07 in 2020. The Biotechs industry in the US is expected to see an average net income growth of 6.3% next year. The consensus price target of US$9.40 was unchanged from the last update. Share price is down by 8.6% to US$2.12 over the past week.Major Estimate Revision • Sep 18Analysts update estimatesThe 2020 consensus revenue estimate increased from US$722.4k to US$922.4k. Earning per share (EPS) estimate remained mostly unchanged at -US$1.21. The Biotechs industry in the US is expected to see a 17% decline in net income next year. The consensus price target of US$9.40 was unchanged from the last update. Share price is up 17% to US$2.54 over the past week.매출 및 비용 세부 내역Genocea Biosciences가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:GNCA.Q 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 222-37154431 Dec 212-33154030 Sep 212-35153730 Jun 210-36153531 Mar 211-43153331 Dec 201-44143430 Sep 201-38143330 Jun 201-41133231 Mar 200-36123031 Dec 190-39122730 Sep 190-29122630 Jun 190-30132631 Mar 190-27142431 Dec 180-28142530 Sep 180-39145830 Jun 180-48145231 Mar 180-59134631 Dec 170-57133930 Sep 170-6215030 Jun 170-5815031 Mar 170-5415031 Dec 160-5015030 Sep 160-4415030 Jun 161-4115031 Mar 161-4015031 Dec 151-4214030 Sep 151-4413030 Jun 151-4312031 Mar 150-4011031 Dec 140-3510030 Sep 140-319030 Jun 140-278031 Mar 140-256031 Dec 131-225030 Sep 131-214030 Jun 131-204031 Mar 132-174031 Dec 122-1540양질의 수익: GNCA.Q 은(는) 현재 수익성이 없습니다.이익 마진 증가: GNCA.Q는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 GNCA.Q의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: 현재 수익성이 없어 지난 1년간 GNCA.Q의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: GNCA.Q은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(43%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: GNCA.Q는 현재 수익성이 없으므로 자본 수익률이 음수(-300.29%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/05/23 13:26종가2023/05/23 00:00수익2022/03/31연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Genocea Biosciences, Inc.는 9명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Michael UlzBairdMara GoldsteinCantor Fitzgerald & Co.Joseph PantginisH.C. Wainwright & Co.6명의 분석가 더 보기
Reported Earnings • Mar 13Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: US$0.48 loss per share (up from US$0.98 loss in FY 2020). Net loss: US$33.2m (loss narrowed 24% from FY 2020). Products in clinical trials Phase I: 2 Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 77%. Over the next year, revenue is expected to shrink by 100% compared to a 60% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
Reported Earnings • Oct 30Third quarter 2021 earnings released: US$0.052 loss per share (vs US$0.082 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$3.62m (loss narrowed 21% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 27Price target decreased to US$5.74Down from US$6.74, the current price target is an average from 5 analysts. New target price is 1,300% above last closing price of US$0.41. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$0.78 next year compared to a net loss per share of US$0.48 last year.
Price Target Changed • Apr 11Price target decreased to US$5.74Down from US$6.70, the current price target is an average from 5 analysts. New target price is 857% above last closing price of US$0.60. Stock is down 77% over the past year. The company is forecast to post a net loss per share of US$0.75 next year compared to a net loss per share of US$0.48 last year.
Reported Earnings • Mar 13Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: US$0.48 loss per share (up from US$0.98 loss in FY 2020). Net loss: US$33.2m (loss narrowed 24% from FY 2020). Products in clinical trials Phase I: 2 Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 77%. Over the next year, revenue is expected to shrink by 100% compared to a 60% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
Price Target Changed • Mar 11Price target increased to US$7.67Up from US$6.68, the current price target is an average from 3 analysts. New target price is 555% above last closing price of US$1.17. Stock is down 60% over the past year. The company is forecast to post a net loss per share of US$0.46 next year compared to a net loss per share of US$0.98 last year.
Board Change • Dec 06Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Jennifer Herron was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 30Third quarter 2021 earnings released: US$0.052 loss per share (vs US$0.082 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$3.62m (loss narrowed 21% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
분석 기사 • Jun 17Here's Why Shareholders May Want To Be Cautious With Increasing Genocea Biosciences, Inc.'s (NASDAQ:GNCA) CEO Pay PacketThe underwhelming share price performance of Genocea Biosciences, Inc. ( NASDAQ:GNCA ) in the past three years would...
Executive Departure • Apr 16Independent Director has left the companyOn the 12th of April, Ronald H. Cooper's tenure as Independent Director ended after 4.8 years in the role. We don't have any record of a personal shareholding under Ronald H.'s name. A total of 2 executives have left over the last 12 months.
Recent Insider Transactions Derivative • Feb 21President exercised options to buy US$132k worth of stock.On the 17th of February, William Clark exercised options to buy 36k shares at a strike price of around US$2.24, costing a total of US$82k. This transaction amounted to 165% of their direct individual holding at the time of the trade. Since March 2020, William's direct individual holding has increased from 17.42k shares to 19.75k. Company insiders have collectively bought US$92k more than they sold, via options and on-market transactions, in the last 12 months.
분석 기사 • Feb 18What Type Of Returns Would Genocea Biosciences'(NASDAQ:GNCA) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?Genocea Biosciences, Inc. ( NASDAQ:GNCA ) shareholders will doubtless be very grateful to see the share price up 77% in...
Analyst Estimate Surprise Post Earnings • Feb 12Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 2.9%. Earnings per share (EPS) exceeded analyst estimates by 2.9%. Over the next year, revenue is expected to shrink by 67% compared to a 819% growth forecast for the Biotechs industry in the US.
Is New 90 Day High Low • Feb 04New 90-day high: US$3.30The company is up 37% from its price of US$2.41 on 05 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 24% over the same period.
분석 기사 • Jan 14How Much Of Genocea Biosciences, Inc. (NASDAQ:GNCA) Do Institutions Own?Every investor in Genocea Biosciences, Inc. ( NASDAQ:GNCA ) should be aware of the most powerful shareholder groups...
Is New 90 Day High Low • Dec 24New 90-day high: US$2.67The company is up 26% from its price of US$2.12 on 24 September 2020. The American market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Oct 31New 90-day low: US$2.08The company is down 27% from its price of US$2.85 on 31 July 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$11.76 per share.
Analyst Estimate Surprise Post Earnings • Oct 31Third-quarter earnings released: Earnings beat expectationsEarnings per share (EPS) surpassed analyst estimates by 69% at -US$0.08. Revenue is expected to shrink by 76% over the next year, compared to a 293% growth forecast for the Biotechs industry in the US.
Major Estimate Revision • Oct 30Analysts increase EPS estimates to -US$1.07The 2020 consensus revenue estimate increased from US$922.4k to US$937.3k. Analysts raised their EPS forecasts from -US$1.21 to -US$1.07 in 2020. The Biotechs industry in the US is expected to see an average net income growth of 6.3% next year. The consensus price target of US$9.40 was unchanged from the last update. Share price is down by 8.6% to US$2.12 over the past week.
Major Estimate Revision • Sep 18Analysts update estimatesThe 2020 consensus revenue estimate increased from US$722.4k to US$922.4k. Earning per share (EPS) estimate remained mostly unchanged at -US$1.21. The Biotechs industry in the US is expected to see a 17% decline in net income next year. The consensus price target of US$9.40 was unchanged from the last update. Share price is up 17% to US$2.54 over the past week.